HOME >> BIOLOGY >> NEWS
Timing of chemical signal critical for normal emotional development

A signaling protein suspected of malfunctioning in anxiety and mood disorders plays a key role in the development of emotional behavior, report researchers funded by the National Institute of Mental Health. Mice lacking it in frontal brain circuits during an early critical period fail to develop normal reactions in anxiety-producing situations.

Rene Hen, Ph.D., Columbia University, and colleagues created mice that lacked the protein, which brain cells use to receive signals from the chemical messenger serotonin, by knocking-out the gene that codes for it. As adults, these "knockout" mice were slow to venture into -- or eat in -- unfamiliar environments. By selectively restoring, or "rescuing" certain populations of the receptor proteins, the researchers have now pinpointed when and where they enable the brain to cope with anxiety. Hen, Cornelius Gross, Ph.D., Xiaoxi Zhuang, Ph.D, and colleagues report on their discovery in the March 28, 2002 Nature.

Brain neurons communicate with each other by secreting messenger chemicals, such as serotonin, which cross the synaptic gulf between cells and bind to receptors on neighboring cell membranes. Medications that enhance such binding of serotonin to its receptor (serotonin selective reuptake inhibitors, or SSRIs) are widely prescribed to treat anxiety and depression, suggesting that the receptor plays an important role in regulating these emotions.

Behavior of the animals in the study mimicked human anxiety. The mice bred not to express the gene that codes for the serotonin receptor (5-HT1A) moved around less than normal animals in open spaces, balked at entering elevated mazes, and were slower to begin eating in such novel environments. Yet, the researchers didn't know which of two populations of serotonin receptors -- one in the forebrain and another deep in the brainstem -- was responsible. To find out, they crossed the receptor knockout mice with mice engineered to turn receptor expres
'"/>

Contact: Jules Asher
NIMHpress@nih.gov
301-443-4536
NIH/National Institute of Mental Health
27-Mar-2002


Page: 1 2 3

Related biology news :

1. Vanderbilt Researcher: Human Brain Has Great Sense Of Timing
2. When To Reproduce? Its All In The Timing
3. DNA lends scientists a hand, revealing new chemical reactions
4. Grant advances biochemical engineering laboratory
5. Bullish chemical could repel yellow fever mosquitoes
6. Computer database being developed at Temple will allow for better inventory of chemicals
7. Cleaner water, more efficient electricity among UH chemical research
8. New world record magnet for chemical and biomedical research
9. Common chemicals morphing into potential toxins in Arctic
10. PTC Therapeutics researchers identify biochemical pathway important for modulating cell growth
11. Research finds lawn chemicals raise cancer risk in Scottish terriers

Post Your Comments:
(Date:5/6/2015)... 6, 2015 LifeBEAM, a developer of bio-sensing ... announced today that they will expand their partnership in ... bio-sensing cycling helmet and the first joint project between ... colors in order to give cyclists more style choices ... LifeBEAM and Lazer announced their plan to release a ...
(Date:4/21/2015)... 21, 2015 High crime ... are boosting access control systems market in ... a recently published report by TechSci Research " Saudi ... access control systems market in Saudi Arabia ... 2020.The access control systems market in the Kingdom is ...
(Date:4/14/2015)... Conn. , April 14, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... been nominated for the 2015 New York Design Awards ... The Design100, New York City Design Awards are part ... based on over 2,500 ratings from the marketplace, industry ...
Breaking Biology News(10 mins):LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
(Date:5/22/2015)... 2015 Knowledgent , the data ... explores the potential of big data analytics in the ... developed to help life sciences and healthcare organizations understand ... gain critical business insights. , The life sciences and ... driven by patient profiling, compliance and regulatory requirements, and ...
(Date:5/21/2015)... Specialty Pharmacy Times has completed ... to BPA Worldwide as a business publication member. ... data for Specialty Pharmacy Times based on business/distribution, ... a member of BPA Worldwide, Specialty Pharmacy Times ... with the most reliable, unequaled data,” said Chris ...
(Date:5/21/2015)... May 21, 2015  The EveryLife Foundation for ... (R-UT) and Amy Klobuchar (D-MN) today ... Cures & Treatments, or OPEN ACT. ... advocacy organizations, this bipartisan legislation promises to rapidly ... to rare disease patients by incentivizing drug makers ...
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation (NASDAQ: ... company specializing in oncology, today announced positive updated ... with aldoxorubicin for the treatment of unresectable glioblastoma ...  The open-label, multisite trial is designed to investigate ... patients whose tumors have progressed following prior treatment ...
Breaking Biology Technology:New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2Specialty Pharmacy Times Joins BPA Worldwide 2Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7
Cached News: